2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1845 Real-world outcomes of autologous stem cell transplantation consolidation versus observation in peripheral T-cell lymphomas.

Baldeep Wirk, MD
1 Virginia Commonwealth University, Richmond, United States

 

Background:  Consolidation with autologous hematopoietic cell transplantation (auto-HCT) for peripheral T-cell lymphomas (PTCL) remains controversial. Prior studies reported mixed results, and interpretation was limited because transplant cohorts were younger and had fewer comorbidities than observation-only cohorts. This study analyzes the impact of auto-HCT versus observation after initial chemotherapy on overall mortality and time to next treatment in PTCL.

Methods:  This retrospective cohort study using the TriNetx Research Network analyzed adults 18 years or older with PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), or ALK-negative anaplastic large cell lymphoma (ALK-negative ALCL) from 2005 to 2025. Cohort 1 (N=479) had auto-HCT within a year of diagnosis after one line of induction chemotherapy. Allogeneic HCT recipients were excluded. Cohort 2 (N=21,104) had chemotherapy only and no autologous or allogeneic HCT. Propensity score matching (1:1) balanced age, gender, race, and relevant comorbidities in the two cohorts. The analysis was conducted within the TriNetX platform using built-in survival and risk assessment tools.

Results: After propensity score matching, baseline characteristics in cohort 1 (N=239) and cohort 2 (N=239) were balanced for age (median 60 [IQR, 16] vs. 59 [IQR, 23] years, p = 0.06); gender (male 55.2% vs 51.5%, p = 0.4); race (White 69% vs 66.9%, p=0.6; Black 7.9% vs 10%, p = 0.4); Hispanic/Latino ethnicity 6.3% vs 6.3%, P=0.5; diabetes (21% vs. 19%, p = 0.6); ischemic heart disease (18% vs. 16%, p=0.2); obesity (19% vs. 15%, p =0.2). Median follow-up was 2 years (IQR, 0.9) for cohort 1 and 2 years (IQR, 1.4) for cohort 2.  

 Kaplan-Meier survival analysis found that the auto-HCT cohort had a significantly greater 2-year survival probability than the observation cohort (82.0% vs 73.0%; Cox HR = 0.60, 95% CI 0.40 to 0.90, log-rank p = 0.02). Consolidation with auto-HCT also significantly prolonged the time to next treatment, yielding a 2-year treatment-free probability of 91.0% versus 74.0% (log-rank p < 0.001). In Cox regression analysis, auto-HCT reduced the need for subsequent therapy by 72% (HR = 0.28, 95% CI 0.17 to 0.48, p < 0.001), satisfying the proportional hazards assumption (p = 0.226).

Multivariable Cox analysis identified age, male gender, stage IV disease, diabetes, and ischemic heart disease as independent predictors of higher mortality (all p < 0.001). Whereas White race (p < 0.001) and Hispanic/Latino ethnicity (p = 0.004) were independently associated with superior overall survival. Black race; specific lymphoma histology PTCL-NOS, AITL or ALK-negative ALCL; obesity class 3 BMI 40 kg/m2 or higher, obesity class 2 BMI 35 -39.9 kg/m2, and obesity class 1 BMI 30-34.99 kg/m2 showed no significant associations with overall survival.

Conclusion: In a real-world cohort of PTCL-NOS, AITL, and ALK-negative ALCL balanced by age, gender, race, and comorbidities, auto-HCT consolidation is associated with significantly reduced overall mortality and the need for next-line therapy.

Baldeep Wirk, MD: No relevant conflicts of interest to declare.